Abstract: The present invention is directed to an insulin formulation comprising a suspension of Ultralente crystals and a total formulation zinc concentration of between about 0.5 milligrams to about 20 milligrams per 100 units of insulin. Greater than fifty percent of the total zinc in the formulation resides in the soluble fraction, rather than in complex with the insulin. This insulin formulation generally has a pH from between about 6.0 to about 7.4. In addition, the insulin formulation of the present invention does not contain other proteins like protamine. This zinc-modified formulation displays characteristics of a very long lasting human insulin product.
Abstract: Monoclonal antibodies which react with the human influx peptide transporter are provided. The human influx peptide transporter-reactive antibodies are useful in the purification of influx peptide transporter and in immunoassays to identify agents taken up into the cell by the human influx peptide transporter mechanism. The monoclonal antibodies are also useful for the detection and treatment of carcinomas derived from the gastrointestinal tract and pancreatic duct.
Type:
Grant
Filed:
June 29, 1993
Date of Patent:
March 19, 1996
Assignee:
Eli Lilly and Company
Inventors:
Stuart W. Bright, Anne H. Dantzig, Linda B. Tabas, J. Richard Sportsman
Abstract: The present invention discloses a human insulin analog hexamer complex and formulations. More specifically, the present invention relates to various parenteral formulations, which comprise: human insulin analogs in a hexamer conformation, zinc ions, and at least three molecules of a phenolic derivative selected from the group consisting of m-cresol, phenol, or a mixture of m-cresol and phenol. The formulation provides a rapid onset of action.
Type:
Grant
Filed:
June 16, 1994
Date of Patent:
December 12, 1995
Assignee:
Eli Lilly and Company
Inventors:
Diane L. Bakaysa, David N. Brems, Bruce H. Frank, Henry A. Havel, Allen H. Pekar
Abstract: Selected acid functional 6-azaindole type derivatives effective as thromboxane synthase inhibitors having the formula (II): ##STR1## where n is an integer from zero to 3, m is an integer from zero to 2, R.sub.1 and R.sub.2 are monovalent radicals, --(L.sub.a)-- is a linking group of 4 to 8 chain atoms, and A is an acidic group.
Type:
Grant
Filed:
January 31, 1994
Date of Patent:
November 21, 1995
Assignee:
Eli Lilly and Company
Inventors:
Joseph A. Jakubowski, Alan D. Palkowitz, Sandra K. Sigmund
Abstract: The present invention provides isolated DNA compounds and recombinant DNA cloning and expression vectors that encode PNB esterase from Bacillus subtilis. The invention also provides host cells transformed with these vectors and a method for production of the PNB esterase by recombinant DNA techniques.
Type:
Grant
Filed:
September 22, 1993
Date of Patent:
November 21, 1995
Assignee:
Eli Lilly and Company
Inventors:
Cathleen A. Cantwell, Roland L. Hodges, Derek McGilvray, Stephen W. Queener, James R. Swartling, Joseph M. Zock
Abstract: A group of 2-amino-3-aroyl-benzo[.beta.]thiophenes are prepared by treating an aldehyde with an anion of dimethylamino thioformamide, cyclizing the .alpha.-hydroxy thioamide, and subsequently acylating the benzo[.beta.]thiophene to yield the 2-amino-3-aryl derivative. These compounds may be treated with suitable phenyl Grignard reagents, and after deprotection, yield 6-hydroxy-2-(4-hydroxyphenyl)-3-[4-(2-piperidinoethoxy)benzoyl]benzo[.beta .]thiophene.
Abstract: A method of inhibiting fertility in women comprising administering to a female human an effective amount of a compound having the formula ##STR1## and pharmaceutically acceptable salts and solvates thereof.
Abstract: Methods of inhibiting vascular smooth muscle cell proliferation and restinosis are disclosed comprising administering to a human or other mammal in need of treatment an effective amount of a compound having the formula ##STR1## wherein R.sub.1 and R.sub.3 are independently hydrogen, --CH.sub.3, ##STR2## wherein Ar is optionally substituted phenyl; R.sub.2 is ##STR3## and R.sub.4 is hydrogen or --OR.sub.1, and pharmaceutically acceptable salts and solvates thereof.
Type:
Grant
Filed:
April 14, 1995
Date of Patent:
October 31, 1995
Assignee:
Eli Lilly and Company
Inventors:
George J. Cullinan, Jai P. Singh, Dan L. Wood
Abstract: The present invention discloses various parenteral pharmaceutical formulations, which comprise: a monomeric insulin analog, zinc, protamine, and phenolic derivative. The analog formulations provide a prolonged duration of action. A process for preparing insulin analog-protamine formulations is also described.
Abstract: The present invention provides novel HIV protease inhibitors, pharmaceutical formulations containing those compounds and methods of treating and/or preventing HIV infection and/or AIDS.
Abstract: A method of inhibiting endometriosis comprising administering to a human in need of treatment an effective amount of a compound having the formula ##STR1## Wherein R.sup.1 and R.sup.3 are independently hydrogen, --CH.sub.3, ##STR2## wherein Ar is optionally substituted phenyl;R.sup.2 is selected from the group consisting of pyrrolidine and piperidino; or a pharmaceutically acceptable salt of solvate thereof.
Type:
Grant
Filed:
October 15, 1993
Date of Patent:
October 24, 1995
Assignee:
Eli Lilly and Company
Inventors:
Larry J. Black, George J. Cullinan, Michael W. Draper, Charles D. Jones, David E. Seyler
Abstract: A method of inhibiting atrophy of the skin or vagina comprising administering to a human in need thereof an effective amount of a compound having the formula ##STR1## wherein R.sup.1 and R.sup.3 are independently hydrogen, ##STR2## wherein Ar is optionally substituted phenyl; R.sup.2 is selected from the group consisting of pyrrolidine, hexamethyleneamino, and piperidino; or a pharmaceutically acceptable salt of solvate thereof.
Abstract: A method for the recombinant production of forms of human protein C with higher activity is described. These forms differ from native protein C in their increased amidolytic and functional activities and novel carbohydrate structures. DNA compounds, vectors, and transformants useful in the method are also disclosed.
Abstract: This invention provides ring-substituted cis-hexahydro-5-(1,2,3,4-tetrahydro-2-naphthalenyl)pyrrolo<3,4-c>pyrroles which are selective inhibitors of serotonin reuptake.
Abstract: Methods of inhibiting vascular smooth muscle cell proliferation and vascular restinosis comprising administering to a human or other mammal in need of treatment an effective amount of a compound having the formula ##STR1## wherein R.sub.1 and R.sub.3 are independently hydrogen, --CH.sub.3, ##STR2## wherein Ar is optionally substituted phenyl; R.sub.2 is ##STR3## R.sub.4 is hydrogen or --OR.sub.1, and pharmaceutically acceptable salts and solvates thereof.
Type:
Grant
Filed:
October 15, 1993
Date of Patent:
October 10, 1995
Assignee:
Eli Lilly and Company
Inventors:
George J. Cullinan, Jai P. Singh, Dan L. Wood
Abstract: A method of inhibiting uterine fibrosis comprising administering to a human or other mammal in need of treatment an effective amount of a compound having the formula ##STR1## Wherein R.sup.1 and R.sup.3 are independently hydrogen, ##STR2## wherein Ar is optionally substituted phenyl; wherein R.sup.2 is selected from the group consisting of pyrrolidino and piperidino, a pharmaceutically acceptable salt or solvate thereof.
Type:
Grant
Filed:
October 15, 1993
Date of Patent:
October 10, 1995
Assignee:
Eli Lilly and Company
Inventors:
Larry J. Black, George J. Cullinan, Michael W. Draper, Charles D. Jones, David E. Seyler
Abstract: The current invention provides a method useful for inhibiting the loss of bone using 6-hydroxy-2-(4-hydroxyphenyl)-benzo(B)thien-3-yl-4[2-(piperidin-1-ethoxyph enol]methanone hydrochloride.
Abstract: The compound 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno-[2,3-b][1,5]benzodiazepine, or an acid salt thereof, has pharmaceutical properties, and is of particular use in the treatment of certain gastrointestinal disorders.